P-GLYCOPROTEIN REGULATES CHEMOSENSITIVITY IN EARLY DEVELOPMENTAL STAGES OF THE MOUSE

被引:27
|
作者
ELBLING, L
BERGER, W
REHBERGER, A
WALDHOR, T
MICKSCHE, M
机构
[1] Tumor Biology-Cancer Research Inst., University of Vienna
来源
FASEB JOURNAL | 1993年 / 7卷 / 15期
关键词
OOCYTES; EARLY CLEAVAGE EMBRYOS; MDR-GENE PRODUCTS; DRUG RESISTANCE; IN-VITRO IN-VIVO;
D O I
10.1096/fasebj.7.15.7903262
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The multidrug resistance (MDR) P-glycoprotein (P-gp) is an active transporter associated with chemoresistance of tumor cells. A fundamental aspect not yet entirely clarified is the physiological role of MDR-P-gp in normal mammalian tissues. In this paper we report that multidrug (chemo)resistance is already present in mouse oocytes and early cleavage embryos. Expression of MDR-specific P-gp is detectable by antibody (C219) staining from the primary oocyte onward to the eight-cell embryo. MDR-mRNA is demonstrated in mature oocytes using an Mdr1-specific cDNA probe. Functional activity of P-gp is shown by the efficacy of MDR reversers (verapamil or quinidine) in enhancement of: 1) drug accumulation (daunomycin) in all stages investigated, 2) drug cytotoxicity (daunomycin or mitomycin C-induced developmental impairment) in two-cell embryos cultured for 24 h, and 3) drug cytokinesis-blocking activity (cytochalasin D; our recent findings demonstrate cytochalasins to be substrates for P-gp and to indicate the presence of MDR by their microfilament-disrupting action on cycling cells) in four- and eight-cell embryos cultured for 24 h. Furthermore, functional involvement of P-gp in vivo is demonstrated. Concurrent administration of verapamil increases doxorubicin-induced developmental impairment in the zygote stage during the first cleavage cycle in pregnant females. Results provide evidence that MDR-P-gp has an efficient protective function in early reproduction.
引用
收藏
页码:1499 / 1506
页数:8
相关论文
共 50 条
  • [1] Inhibitor of P-glycoprotein increases chemosensitivity
    Ahmad, Khabir
    [J]. LANCET ONCOLOGY, 2007, 8 (02): : 101 - 101
  • [2] LABORATORY ASSESSMENT OF P-GLYCOPROTEIN IN CANCER CHEMOSENSITIVITY TESTING
    WEINSTEIN, RS
    COON, JS
    [J]. HUMAN PATHOLOGY, 1990, 21 (08) : 785 - 786
  • [3] Refined structures of mouse P-glycoprotein
    Li, Jingzhi
    Jaimes, Kimberly F.
    Aller, Stephen G.
    [J]. PROTEIN SCIENCE, 2014, 23 (01) : 34 - 46
  • [4] Refined Structures of Mouse P-Glycoprotein
    Aller, Stephen G.
    Li, Jingzhi
    Jaimes, Kimberly
    [J]. BIOPHYSICAL JOURNAL, 2014, 106 (02) : 790A - 790A
  • [5] Relationship of P-glycoprotein and p53 protein to chemosensitivity in colorectal cancer
    Yagi K.
    Kunitomo K.
    Ii K.
    Tashiro S.
    [J]. International Journal of Clinical Oncology, 1997, 2 (2) : 81 - 91
  • [6] Multidrug resistance in glioblastoma. Chemosensitivity resting and immunohistochemical demonstration of p-glycoprotein
    Leweke, F
    Damian, MS
    Schindler, C
    Schachenmayr, W
    [J]. PATHOLOGY RESEARCH AND PRACTICE, 1998, 194 (03) : 149 - 155
  • [7] P-Glycoprotein modulation improves in vitro chemosensitivity in malignant pediatric liver tumors
    Warmann, S
    Göhring, G
    Teichmann, B
    Geerlings, H
    Pietsch, T
    Fuchs, J
    [J]. ANTICANCER RESEARCH, 2003, 23 (6C) : 4607 - 4611
  • [8] Regional expression of P-glycoprotein in adult mouse brain
    Daood, MJ
    Tsai, C
    Hansen, TWR
    Watchko, JF
    [J]. PEDIATRIC RESEARCH, 2000, 47 (04) : 395A - 395A
  • [9] P-glycoprotein expression in mouse brain increases with maturation
    Tsai, CE
    Daood, MJ
    Lane, RH
    Hansen, TWR
    Gruetzmacher, EM
    Watchko, JF
    [J]. BIOLOGY OF THE NEONATE, 2002, 81 (01): : 58 - 64
  • [10] Disposition of cisapride appears to be influenced by P-glycoprotein in the mouse
    Choo, EF
    Venkatakrishnan, K
    Hatch, HL
    Rahematpura, S
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (03) : 225 - 226